FDA Approved: VANFLYTA — Supplemental Application (Daiichi Sankyo Inc.)

View source ↗

Summary

FDA approved a supplemental application for VANFLYTA (quizartinib) submitted by Daiichi Sankyo Inc., resulting in changes to the drug's labeling and/or indicati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VANFLYTA (quizartinib)

Snippet

SUPPL AP for VANFLYTA (QUIZARTINIB)